Boston Partners
NBIX icon

Boston Partners’s Neurocrine Biosciences NBIX Stock Holding History

Boston Partners’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.99M Buy
59,268
+12,980
+28% +$1.93M 0.01% 450
2026
Q1 		$6.1M Sell
46,288
-8,184
-15% -$1.09M 0.01% 469
2025
Q4 		$7.73M Buy
+54,472
New +$7.89M 0.01% 441

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Boston Partners's NBIX Position: Q2 2026 in Review

Boston Partners increased its Neurocrine Biosciences (NBIX) stake by 28% in Q2 2026, buying an estimated $1.93M and bringing the position to 59,268 shares worth $9.99M. The position accounts for 0.01% of the portfolio, ranked #450.

Boston Partners first reported a position in NBIX in Q4 2025 and has held it in 3 quarters since. 624 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Boston Partners held 59,268 shares of Neurocrine Biosciences worth $9.99M as of Q2 2026.
  • Boston Partners bought 12,980 Neurocrine Biosciences shares in Q2 2026, an estimated $1.93M.
  • Neurocrine Biosciences made up 0.01% of Boston Partners's portfolio in Q2 2026, its #450 holding.
  • Boston Partners first reported a position in Neurocrine Biosciences in Q4 2025 and has held it in 3 quarters since.
  • 624 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Boston Partners's 13F filing for Q2 2026, filed 4 Aug 2026.